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Abstract
Overall, approximately 95 percent of reported cases of vector-borne disease were
associated with ticks, making these the most medically important group of arthropods in the
United States.1 Despite the prevalence of tick-borne infections, the process for the diagnosis of
this condition is not well studied. This study aims to analyze data from a pool of 100 patients who
underwent testing for tick-borne disease in the same institution in Dover, New Hampshire during
the most recent peak tick season of 2019. Information utilized in this study included: patient age,
sex, location of testing (inpatient versus outpatient), diagnostic testing methods used pertaining
to investigation of tick-borne disease, results of tick-borne panel testing, number of days to
obtain tick panel results, symptomology, treatments pertaining to the investigation of tick-borne
disease, and record of follow-up visits. Analyses of these data points revealed a trend that
suggests the current diagnostic process for tick-borne disease is unnecessarily burdensome for
patients and medical facilities. There is a need for a faster turnaround time in testing to decrease
the need for supplemental tests and follow-up visits pertaining to the investigation of tick-borne
diseases. This study also suggests that recognition of symptoms associated with positive results
is paramount to improve the detection of tick-borne illnesses. Further investigation of our
current methods and possible future adaptations to them are critical if we are to conquer the
diverse array of challenges presented by tick-borne diseases.
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Introduction
Ticks transmit the most diverse array of infectious agents of any arthropod vector. Both
ticks and the microbes they transmit are recognized as significant threats to human and
veterinary public health. Greater than 60% of human infectious diseases emerging between 1940
and 2004 were zoonotic, resulting in significant global morbidity, mortality, and economic costs.2
During 2013, 48,821 cases of autochthonous, nationally notifiable, vector-borne disease were
reported to the United States Centers for Disease Control and Prevention (CDC). Overall,
approximately 95 percent of reported cases of vector-borne disease were associated with ticks,
making these the most medically important group of arthropods in the United States. 1 Lyme
disease alone accounted for almost 75 percent of all reported cases of indigenously acquired
vector-borne disease.1 Lyme disease is the most commonly reported vector-borne illness in the
United States. Since the institution of Nationally Notifiable surveillance efforts for Lyme disease
in the United States in 1991, there has been a consistent increase in the number of reported
cases. Thus, the need for targeted prevention strategies is underscored.3 Additionally from 2000
to 2007, the incidence of infections caused by Anaplasma phagocytophilum and Ehrlichia
chaffeensis, two tick-borne pathogens, increased linearly from 0.80 to 3.0 and 1.4 to 3.0 cases
per million population, respectively.1 Nonetheless, the true incidence of tick-borne disease is
likely greatly underestimated, as patients with presumed infections are rarely tested for the full
range of tick-borne agents, and only a fraction of positive cases are properly reported.4
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Lyme disease, babesiosis, anaplasmosis, ehrlichiosis, and Powassan virus infection are the
most prevalent diseases transmitted by ticks in the United States, all of which are endemic in the
New England and upper Midwestern regions.3,5 Diagnosis of these conditions is largely reliant on
blood testing panels that utilize a whole blood sample to detect the presence of genetic material
of a list of organisms. The Accutix panel offered by Imugen, a reference laboratory operating in
Norwood,

Massachusetts,

consists

of

Babesia

microti

DNA

detection,

Anaplasma

phagocytophilium DNA testing, Ehrlichia chaffeensis DNA detection, Borrelia species DNA
detection, and Lyme Antibody analysis.6

Babesia are malaria-like protozoans that parasitize and reproduce within mammalian red
blood cells. They have a complex life cycle involving several different stages and physical forms
and are maintained in nature primarily via exchange between Ixodes ticks and various mammals,
such as deer and mice.7,8 In the United States, the primary agent of human babesiosis is Babesia
microti, which is transmitted by the bite of Ixodes scapularis, the same tick species that vectors
Lyme disease. Cases of babesiosis caused by B. microti occur in southern New England and the
northern Midwest. Although primarily transmitted by tick bite, babesiosis can also be acquired
via blood transfusion and maternal-fetal transmission.8 Babesia infection can range from
asymptomatic to life threatening. Risk factors for severe babesiosis include asplenia, advanced
age, and impaired immune function. Severe cases can be associated with marked
thrombocytopenia, disseminated intravascular coagulation (DIC), hemodynamic instability, acute
respiratory distress, renal failure, hepatic compromise, altered mental status, and death. 5
Symptoms commonly seen in Babesia infection include malaise, headache, fatigue, fever, chills,
7

sweats, gastrointestinal symptoms (anorexia and nausea), and in some occurrences mild
splenomegaly, mild hepatomegaly, and jaunice. 5 Laboratory findings might indicate decreased
hematocrit due to hemolytic anemia, thrombocytopenia, elevated serum creatinine and blood
urea nitrogen (BUN), and/or mildly elevated hepatic transaminase values.5 Primary diagnostic
methods are the identification of intraerythrocytic Babesia parasites via light microscope of
blood smear, Babesia polymerase chain reaction (PCR), isolation of Babesia parasites from a
whole blood specimen by animal inoculation, and antibody detection by indirect fluorescent
antibody (IFA) testing for total immunoglobulin (Ig).5 The non-specific symptomology and
unremarkable physical presentation can make babesiosis difficult to detect. Physicians should be
alert to test for this condition with the presentation of flu-like symptoms in the summer months.
Limitations in testing are plentiful. It may be difficult to detect in early stages in a peripheral blood
smear, IFA antibody detection does not necessarily indicate active infection since antibodies can
be found in serum long after infection, and PCR may not be able to detect the organism in an
early infection if the titer is not high enough. Coinfection with Lyme disease or anaplasmosis may
also complicate the clinical presentation and predispose the patient to more severe disease. 8

Another tick-borne pathogen endemic to the Northeast is Anaplasma phagocytophilum.
This organism is an obligate gram-negative, intracellular bacterium that causes an acute febrile
illness known as anaplasmosis or human granulocytic anaplasmosis (HGA), formerly known as
Human Granulocytic Ehrlichiosis (HGE).5 The organism is genetically related to Rickettsia and is
transmitted by Ixodes scapularis in the northeast United States and by Ixodes pacificus in
California. The vector also transmits other organisms responsible for diseases such as Lyme,
8

babesiosis, ehrlichioses and Powassan encephalitis. 9 A. phagocytophilum infection is acquired
through a tick bite and disseminates to the bone marrow and spleen where it can evade
neutrophil antimicrobial functions.9 Severe and life-threatening illness is less common with
anaplasmosis compared to other rickettsial diseases, such as Rocky Mountain spotted fever
(RMSF) or E. chaffeensis ehrlichiosis. While the case-fatality rate among patients who seek
care for the illness is <1%, predictors of a more severe course include advanced age,
immunosuppression, comorbid medical conditions, and delay in diagnosis and treatment. 5
Anaplasmosis generally presents with nonspecific symptoms such as fever, chills, malaise,
headache, and myalgias. On rare occasions, a rash may be present. The patient may also
report nonspecific gastrointestinal (GI) or respiratory symptoms. 9 In the first weeks of infection
laboratory findings may include a mild anemia, thrombocytopenia, leukopenia, and/or elevations
in hepatic transaminases. Diagnosis is primarily accomplished by PCR analysis, IgG antibody titer
by IFA, and immunohistochemical staining of organism from skin, tissue or bone marrow biopsies.
Since antibody titers are often negative in first 7-10 days after infection and PCR is most sensitive
during first week of infection, there are limitations in our current standards of testing for this
condition.5

Ehrlichia chaffeensis is another prevalent pathogen transmitted by Ixodes ticks. E.
chaffeensis is an obligate intracellular Gram-negative bacterium that causes Human Monocytic
Ehrlichiosis (HME). Signs and symptoms of ehrlichiosis typically begin within 1-2 weeks after the
bite of an infected tick. The most common symptoms include a fever with headache, myalgia,
and malaise, and a rash can be observed in up to 33% of patients.10 Gastrointestinal, respiratory,
9

or central nervous system involvement also may occur in more serious manifestations. Currently
most infections are not diagnosed, but HME can be a life-threatening disease, with
hospitalization in 41-63% of recognized cases. Severely affected patients can develop acute
respiratory failure, renal failure, meningoencephalitis, coagulopathy, and GI bleeding. Untreated
disease may progress to death as early as the second week of illness. 10 Available diagnostic tests
include IFA (some cross reactivity with other Ehrlichia species is possible), western blot, PCR,
visualization of morulae (intraleukocytic clusters of bacteria) in a blood smear,
immunohistochemical staining, and isolation.10 As with other diseases detected by these
methods, the diagnosis of E. chaffeensis is complicated by the possibility of false positives if the
infection level is below sensitivity parameters, particularly in microscopic and PCR methods.
Seeing as this infection is carried by the same vector as several other tick-borne pathogens,
diagnosis can also be affected by coinfection. Coinfecting pathogens may cause competition in
the PCR reaction, since significantly higher concentrations of one pathogen compared with the
others can result in the detection of only one organism. 11

The spirochetes include several human pathogens, including Treponema pallidum (agent
of syphilis), Leptospira interrogans (leptospirosis), and several Borrelia spp. that cause relapsing
fever.11 The spirochete Borrelia burgdorferi is a tick-borne obligate parasite whose normal
reservoir is a variety of small mammals. Whereas infection of these natural hosts does not lead
to disease, infection of humans can result in Lyme disease, as a consequence of the human
immunopathological response to B. burgdorferi. The organism has a distinctive morphology that
includes a spiral or wavelike body and flagella (organs of motility) enclosed between the outer
10

and inner membranes. Ticks of the genus Ixodes transmit B. burgdorferi between hosts and are
the only natural agents through which humans have been shown to become infected. In the
northeastern and midwestern United States, the primary tick species for human disease is Ixodes
scapularis (the black-legged tick) and in the western states I. pacificus (the western black-legged
tick) is the main agent of dissemination.11 In 2015, 95% of Lyme disease cases were reported from
14 states: Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire,
New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia, and Wisconsin. 5 Ticks most
frequently acquire spirochetes from infected rodents during their larval feeding. Both nymphs
and adults occasionally feed on humans, but the small size of the nymphs makes them difficult
to detect and, hence, more likely to feed long enough to transmit the spirochete and cause Lyme
disease.11 In the localized stage of Lyme disease, Erythema migrans (EM), a red ring-like or
homogenous expanding rash; is a classic indicator of Borrelia infection but may not always be
present. More common symptoms are flu-like, such as malaise, headache, fever, myalgia,
arthralgia, and lymphadenopathy. During the localized (early) stage of illness, Lyme disease may
be diagnosed clinically in patients who present with an EM rash. Serologic tests may be
insensitive at this stage. During disseminated disease, however, serologic tests should be
positive.5 The disseminated stage is a later stage that may cause multiple secondary annular
rashes, more severe flu-like symptoms, and lymphadenopathy. Rheumatologic, cardiac and
neurologic manifestations are also possible at this point in infection. 5 Most notable laboratory
findings include an elevated erythrocyte sedimentation rate, mildly elevated hepatic
transaminases, and microscopic hematuria or proteinuria. In Lyme meningitis, cerebrospinal fluid
typically shows lymphocytic pleocytosis, slightly elevated protein, and normal glucose. 5 Diagnosis
11

is primarily achieved through demonstration of diagnostic IgM or IgG antibodies in serum. A twostep testing protocol is recommended, the first step being serological antibody analysis and the
second being confirmation via western blot. 5 Coinfection with B. microti and/or A.
phagocytophilum should be considered in patients who present with initial symptoms that are
more severe than are commonly observed with Lyme disease alone, especially in those who have
high-grade fever for more than 48 hours despite appropriate antibiotic therapy or who have
unexplained leukopenia, thrombocytopenia, or anemia. Coinfection should also be considered in
patients whose erythema migrans skin lesion has resolved but have persistent flu-like
symptoms.5 As will all aforementioned tick-borne pathogens, testing limitations are abundant. In
serological testing the sensitivity and specificity are not always high enough to be detected, and
cross-reacting immunoglobulins can be a problem in many cases. Genetic detection by PCR is
successful only during acute infection when levels of the analyte are found at high enough
concentrations in a blood specimen. Also, given the organism’s spirochete morphology, it can be
difficult to observe using traditional microscopic techniques and may require special staining and
dark microscopy.

Even with the true incidence of tick-borne disease likely being greatly underestimated by
epidemiological data, studies of trends over the last few decades have demonstrated that this
group of infections have emerged or re-emerged in many geographical regions.12 Yet the precise
diagnosis of many of these diseases still remains a major challenge because of the lack of
comprehensive data available on accurate and reliable diagnostic methods. 12 The diagnostic
process is further complicated by the many limitations on the available testing strategies in
12

current practice. Identification of pathogens in biological samples has been dominated by the use
of culture-dependent methods, conventional molecular approaches, and serological tests. 12 In
regards to tick-borne infections, these methodologies suffer from major limitations. Microscopy
remains an important part of laboratory testing for the diagnosis of most tick-borne diseases,
especially in resource-limited settings, but it is highly subjective and dependent on experience
and training.12 In a modern diagnostic laboratory setting, the time constraint and expertise that
microscopy requires prevents this method from being used on most samples unless specifically
mandated by a physician. Cell culture procedures are time consuming, and isolation of pathogens
is not always successful. The specificity and the sensitivity of serological tests are not always
optimal, and cross-reactions are a common problem.12 With the upward trends the health
community is seeing in this group of infections, it will become imperative to adapt our current
standards of diagnosis to more accurately and quickly treat affected patient populations. To
better understand these issues, this study aims to analyze data from a pool of 100 patients who
underwent testing for tick-borne disease in the same institution in Dover, New Hampshire during
the most recent peak tick season of 2019. It is here that we quantify and elaborate on the biggest
challenges in detecting tick-borne disease with the goal of identifying possible pitfalls in current
tick-borne diagnostic practices.
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Materials and Methods
This study was based on results obtained through the electronic medical records of 100
random, fully de-identified patients who received tick panel testing through WentworthDouglass Hospital in Dover, New Hampshire from April 1st to July 31st of 2019. Approval of the
retrieval of this de-identified information was granted from the Institutional Review Boards of
the University of New Hampshire (IRB #8122) as well as Wentworth-Douglass Hospital in August
2019. From the time period of August 2019 to November 2019, data collection was performed
on the WDH campus from a computer within the hospital network. Here, information was
extracted, organized, and de-identified from the electronic medical records. The Safe Harbor
method for de-identification of protected health, a HIPAA compliant way to remove specific
identifiers from a data set, was used in the collection of data.13 The electronic medical records
were obtained through multiple hospital software systems. Soarian Clinicals was used to access
information on the testing results from all departments within the laboratory as well as outside,
such as cardiology and radiology. Soarian Electronic Documents Manager was utilized to view all
documentation under the patient profile, this includes intake forms, triage nurse notes,
hospitalist notes, and treatment notes. NextGen is the software containing information on most
outpatients such as phone call records, drug prescriptions, and follow-up appointments. SoftLab
is the laboratory software which provided the results of the tick panel for each patient as well as
all other laboratory testing. From a hospital device on the WDH campus, the medical history of
100 random patients was accessed and manually transferred and simultaneously de-identified to
an Excel spreadsheet on a private device outside the hospital network. This relevant information
included: patient age, sex, location of testing (inpatient versus outpatient), diagnostic testing
14

methods used pertaining to investigation of tick-borne disease, results of tick-borne panel
testing, number of days to obtain tick panel results, symptomology of the patient, treatments
pertaining to the investigation of tick-borne disease, and record of follow-up visits pertaining to
initial symptoms of tick-borne disease. After collection of each of these data points on all 100
patients, analyses and generation of figures was done using the original Excel spreadsheet where
data was stored. Figures were generated using formulas in Excel and charting tools within the
software.

Results
Patient Demographics
The total number of patients analyzed (100) was partitioned into age groups. The age
groups (in years) were under 21, 21-30, 31-40, 41-50, 51-60, 61-70, and 71+. Each age group was
then further divided into males and females. The under 21 age group comprised a total of 7
patients, 5 of them being female and 2 being males. The 21-30 age group totaled 18 patients, 12
female and 6 male. The 31-40 age group comprised a total of 9 patients, 4 female and 5 male.
The 41-50 age group consisted of 13 patients, 11 female and 2 male. The 51-60 age group
comprised a total of 23 patients, 8 female and 15 male. The 61-70 age group totaled 17 patients,
5 female and 12 male. The 71+ age group consisted of 13 patients, 5 female and 8 male (Fig. 1A).

Data on each of the 100 patients included the location which the initial visit occurred. All
the locations were simplified into three categories: inpatients, outpatients, and emergency room
patients. The number of patients in each group was 11, 49, and 40 respectively (Fig. 1B).
15

Figure 1. Patient Demographics. A. The age ranges for the 100 patient pool spans from under 21
years to 71+ years. Both males and females are represented in each age range. B. The location of
the initial visit for each patient is shown via three groups, Hospital inpatients, outpatients, and
emergency room patients.

Clinical Presentation
Within the 100 patient pool the most commonly reported symptoms were determined.
They included: fatigue, dizziness, vomiting, nausea, headache, myalgia, fever, and erythema
16

migrans/rash/tick bite. For each symptom the total number of patients reporting it were
determined as well as the amount of those patients that were positive for any organism detected
via PCR and positive for any immunoglobulins detected by serology. Seeing as patients could
report more than one symptom, the number of patients reporting should not be considered as
part of the total 100 but rather part of the group of all patients reporting the symptom. Nine
patients reported fatigue, 2 of them PCR positive and 1 serology positive. Dizziness was reported
by 6 patients, only 1 of which was positive for PCR. Vomiting was reported in 3 patients, each
were negative in PCR and serology testing. Nausea afflicted 11 patients, 2 PCR positive and 1
serology positive. Twenty patients reported headaches, 5 were PCR positive and 2 were serology
positive. Forty-five patients reported myalgia as a symptom, of which 3 were PCR positive and 8
were serology positive. Fever was reported by 27 patients, 5 were PCR positive and 3 were
serology positive. Twenty-eight patients reported having erythema migrans, a rash, or a tick bite,
4 were PCR positive and 5 were serology positive (Fig. 2A).
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Figure 2. Clinical Presentation. A. The most common symptoms as reported by a nurse or
physician along with the total number of patients that reported that symptom, the number of
PCR positive patients with that symptom, and the number of serology positive patients with that
symptom.

Diagnostic Process
As part of the diagnostic protocol, patients underwent testing other than an Accutix
panel. Within the hospital, patients received testing results from radiology, cardiology and the
laboratory. Within each of these departments, the most reported testing procedures were
identified. In radiology, patients could have undergone a CT scan, an MRI, other specialty
imaging, ultrasounds, or an X-ray. In cardiology, some patients received cardiac analysis from a
specialist. In the laboratory, cultures of blood, urine, and other body fluids could have been done,
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in addition to Flu testing and the Monospot which detects Epstein-Barr virus. In radiology, 14
patients had a CT scan, 2 had MRI’s, 3 had specialty imaging, 1 had an ultrasound, and 1 had an
X-ray. Three patients saw a cardiac specialist in the cardiology department. In the laboratory, 9
patients had cultures, 2 got tested for the flu, and 4 were reported as having done a Monospot
test (Fig. 3A).

All 100 patients obtained results from an Accutix panel test, consists of Babesia microti
DNA detection, Anaplasma phagocytophilium DNA testing, Ehrlichia chaffeensis DNA detection,
Borrelia species DNA detection, and Lyme Antibody analysis. All DNA detection was performed
via PCR, and antibody analysis was done via serology. The results of the panel were as follows:
negative PCR for all organisms, positive PCR for 1 organism, positive PCR for 2 organisms, and
positive Lyme antibody serology. The number of patients with those results was 89, 11, 0, and 16
respectively. An additional result of note is a positive Borrelia PCR and positive Lyme antibody
serology, which only 1 patient had (Fig. 3B).

The Lyme antibody serology analysis detected three immunoglobulins, IgG, IgA, and IgM.
A positive serology result could be positive for IgM, IgG, IgA, or a combination of IgM and IgG,
IgM and IgA, IgG and IgA, or all three immunoglobulins. The number of patients with positive IgM
only was 11, 3 patients were positive for only IgG, and 2 were positive for only IgA. Patients with
both IgM and IgG totaled 2, while the other two combinations had no patients. One patient was
positive for all three immunoglobulins (Fig. 3C).
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Each of the 100 patients had an Accutix panel tested at a reference laboratory with results
sent electronically back to the hospital laboratory. For each patient, the time (in days) between
the blood sample draw and the testing on the sample was calculated. Most patients (33) had a 4
day time, 22 patients had 5 days, 20 had 3 days, 10 patients had 2 days, 8 patients had 6 days, 4
patients had 7 days, 2 patients had 8 days, and 1 patient had a 1 day time until testing was done
(Fig. 3D).

Figure 3. Diagnostic Process. A. The most common reported supplemental methods of diagnosis
grouped by departments radiology, cariology, and laboratory, and the number of patients whose
records indicated diagnostic procedures in each. B. Number of patients with each possible result
from testing in both serology and PCR analysis. C. The number of patients with each combination
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results of immunoglobulins IgG, IgA, and IgM. D. The time (days) between when the patient
sample was sent for testing and the test was performed in a reference laboratory.

Treatment Management
The medications used to treat each of the 100 patients that were reported in the patient
documentation can be categorized into analgesics, antibiotics, antihistamines, steroids, and
other substances not belonging to any category. The number of patients in each was quantified.
In the analgesics, 2 patients were given aspirin, 14 were recommended ibuprofen, 6 were given
ketorolac, 30 received acetaminophen, and 4 were given Zofran. Of the antibiotics, 2 patients
took amoxicillin, 2 had ceftriaxone, 35 took doxycycline, and 2 had vancomycin. The only
antihistamine was Benadryl, which was given to 3 patients. Prednisone, the only steroids, was
prescribed to 4 patients. Fluids were administered to 22 patients (Table 1).
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Table 1. Treatment Management. The most common reported substances for treatment
categorized into drug classes analgesics, antibiotics, antihistamines, steroids, and other
substances along with the number of patients who received that treatment.

Incidence of Follow-Up
Based on patient visit information on the hospital software, the incidence of follow-up
visits at facilities in the hospital network pertaining to the investigation of tick-borne disease was
quantified. Of the 100 patients, 42% did have a documented follow-up visit and 58% did not
(Table 2).

Table 2. Incidence of Follow-up. The percentage of patients whose record indicated a follow-up
visit pertaining to the investigation of tick-borne disease compared to the percentage of patients
whose record did not indicate a follow-up.

Discussion
The pool of 100 patients who underwent testing related to a possible tick-borne disease
consisted of 50 men and 50 women ranging in age from under 21 to 71+ years. Most of the
patients, 66%, were 41 years and older, and the category with the lowest number of patients was
the under 21 group. This is not surprising considering the group most at-risk in acquiring tick-
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borne diseases are older patients with weaker immune systems.14 The majority of patients (23%)
were ages 51-60, and within this category was also the highest number of patients from a single
gender, 15 males. The high number of patients in this age range could be suggestive of an at-risk
lifestyle in this population. People between 51-60 are at or close to retirement age and likely own
their own homes, meaning their summers may largely be spent on lawn care. Patient in this age
range are particularly at-risk in acquiring tick-borne infections since they are still active enough
to become exposed, but may not have strong enough immunity to protect themselves from
infection.14
When a patient begins the process to receive tick panel testing on their blood sample,
they are often in one of three locations. They are either a hospital inpatient, an outpatient at a
clinic, or an emergency room patient. Hospital inpatients are the least healthy of all these
populations seeing as they are already in the hospital being cared for due to a different cause.
Not surprisingly, this group of patients totals only 11 out of the 100 studied. This is most likely
because these patients are not outside becoming exposed to ticks, but still do have symptoms
that might warrant tick panel testing. It is the outpatients that make up a total of 49%, the most
of any population, with emergency room patients having just a slightly lower total of 40%. These
two populations present the most risk considering they are more likely to be spending their days
outside becoming exposed to ticks. One reason outpatients might outnumber emergency room
patients would be based on the preference of most patients. Most people prefer to visit a walkin clinic rather than face a trip to the emergency room which is usually more expensive.15 If a
patient has only headaches or a mild rash, it is unlikely they treat this as an urgent enough issue
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and make a trip to the hospital where longer wait times and expensive bills are real
consequences.
The symptomology of each patient was based on reports from nurse practitioners and
doctors who assessed the patient and recommended or administered treatment. The most
common symptom reported was myalgia, or muscle pain, which comprised a total of 45 patients.
The group of patients who reported this symptom also had the highest number of serology
positive people, 8 total, and had 3 people who were PCR positive. The next highest reported
symptom was erythema migrans/rash/tick bite which had 28 patients total. Five of these patients
were serology positive and 4 were PCR positive. This is interesting seeing as erythema migrans
has long been considered a hallmark symptom of Lyme disease,16 and yet only 11 patients who
reported this symptom and others like it were serology or PCR positive. This study may beg the
question as to whether this clinical presentation should be given the weight that it currently holds
in the diagnostic process. The third most commonly reported symptom was fever, which
occurred in 27 patients, 3 being serology positive and 5 being PCR positive. Patients with fever
and patients with a headache (20 total) were tied for most PCR positive patients at a total of 5.
The lowest reported symptom was vomiting with 3 patients (none positive) and dizziness with 6
patients (1 PCR positive). This information can be helpful in differentiating the likelihood of
positive results based on symptomology. Patients presenting with myalgia were mostly serology
positive, which is not likely reflecting a current infection but perhaps a prior infection that has
been treated. Patients with PCR positivity indicating an acute infection were mostly comprised
of those presenting with fever and/or headache. Fatigue was only reported in 9 patients with 2
testing PCR positive and 1 serology positive. Considering that fatigue or malaise is a chief
24

symptom of tick-borne disease,16 it is interesting that it was reported in so few cases. This may
indicate that more attention should be put on those suffering myalgias and fevers than those
who are fatigued, nauseous, vomiting, or experiencing dizziness regarding tick-borne diseases.
In addition to submitting a blood sample for Accutix panel testing, many of the 100
patients were reported as having other supplemental diagnostic testing done in hospital
departments. The most commonly utilized departments were radiology, cardiology, and the
hospital laboratory. Of the testing done in radiology, CT scans were reported by the most patients
of all the departments at 14%. In the laboratory, 9 patients had other cultures performed, 2 had
flu testing, and 4 had a Monospot test. Three patients underwent cardiac analysis in cardiology.
The total percentage of patients who had reported supplemental testing was 39%, meaning that
a considerable amount of people underwent additional testing while their Accutix results were
pending. This trend creates a large burden for the testing facility and the patients undergoing
testing. Seeing as this testing is often done in the days before the reference laboratory performs
the Accutix testing, this extra cost could theoretically be eliminated if the results were returned
at a faster rate.
Seeing as the Accutix panel is comprised of PCR analysis of four different organisms and
a Lyme antibody serology analysis, there are several kinds of testing results that patients could
obtain. The result belonging to most patients, 89, was negative PCR analysis. The remaining 11
patients out of the 100 were positive in PCR for one organism. There were no patients who tested
positive in PCR for 2 or more organisms. Of the 100 patients, 16 total tested positive in Lyme
antibody serology. There was only one patient who tested positive for Borrelia species PCR and
Lyme serology, which is interesting considering people with Borrelia infection are expected to
25

have positive results in both of these analyses.17 This number could indicate that it is not often
that patients are going to reflect both active infection and immune response during testing. Most
patients are either in an acute phase where DNA is present and antibodies are not yet detectable,
or they are in a recovered phase where antibodies are still present but the DNA of the organism
is not detectable.17 This information could be valuable in assessing the window period of infection
and comparing it to when patients are most likely going to see symptoms that prompt a visit to
their clinic for testing.
In the patient population who tested positive in Lyme antibody serology, there are three
immunoglobulins for which a person could be positive, IgG, IgM and IgA. The sole presence or
combination of any (or all) of these immunoglobulins provides important diagnostic information
which helps determine what stage of infection the patient might be in.17 In the pool of 100
patients, most people who tested positive in serology had IgM (11 patients). IgG was only found
in 3 patients and IgA was found in 2. Since IgM is the first antibody produced upon infection, this
could indicate that most people who tested positive were in an early response stage of infection,
which often occurs at least ten days after the initial exposure.18 The low prevalence of IgG
immunoglobulins in this patient population indicates that there were not many cases of recurring
infection, where IgG is expected to be found in higher concentrations than IgM. 18 These figures
offer a valuable insight as to the stage of infection that most patients present with at the time of
testing.
Since the Accutix panel testing is done at a reference laboratory outside the hospital,
there is a wait time between when the specimen is collected and when it is tested. This time is
expressed in days and is calculated from the laboratory reports from each of the 100 patients.
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About one third of patients, 33 of them, had a 4 day wait time for their Accutix testing. There
were 22 patients who had a wait time of 5 days and 20 patients who waited 3 days. Seeing as
most patients had more than a couple days to wait for their results, it is likely that in this time
patients underwent other testing and further investigation of their symptoms pending their panel
results. This presents a greater economic burden to the patient, and the testing might not
ultimately be necessary depending on the actual diagnosis the patient receives. The time and
resources of the different departments being handed these patients while they are waiting for
off-site results is also significant and presents a challenge for the facility.
Of the treatment that was most commonly reported amongst the 100 patients, most can
be categorized by drug class. These include analgesics, antibiotics, antihistamines, steroids, and
other substances. The most noteworthy treatments were the analgesics Ibuprofen and
Acetaminophen which were used by 14 and 30 patients respectively, and the antibiotic
doxycycline which was prescribed to 35 patients. Fluids were either recommended or
administered via IV to a total of 22 patients. This data reveals that the way tick-borne testing is
treated is mostly palliative care and low-grade pain management. The most common antibiotic
used is doxycycline which is almost always written as a 100 mg pill taken twice per day for at least
ten days. Although doxycycline has been shown to be effective against tick-borne disease,19,20
the problem of over-prescription must be considered. Since many patients given this antibiotic
are prescribed in leu of Accutix results being released, there are a considerable number of
patients taking a course of antibiotic they likely don’t need. The consequence of over-use of
antibiotics has long been investigated as a cause of antibiotic resistance.21 If the medical
community relies too heavily on doxycycline, it is simply a matter of time before the organisms
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we are attempting to combat debut a mutation that allows resistance in the next tick season.
With the prevalence of tick-borne disease today, it is likely that our treatment for this type of
infection will have to become more targeted if we are to prevail over these pathogens in the
future.
The incidence of follow-up visits at facilities in the hospital network pertaining to the
investigation of tick-borne disease was quantified. Of the 100 patients, 42% did have a
documented follow-up visit and 58% did not. These follow-ups in 42 of the studied cases could
have been a visit with a specialist, an appointment for scanning in radiology, a primary care
physician visit, or an emergency room or outpatient facility visit for worsening symptoms. All of
these types of visits pertain to the diagnostic investigation of tick-borne illness. It is important to
consider that almost half of this small population of patients returned for a follow-up, and this
figure is likely underestimated seeing as patients could have made an appointment outside of
the hospital network. This high percentage of follow-ups present two problems; the first being a
heavy financial burden on the patient and the second being the large amount of time and
resources spent on these patients by the hospital. There are benefits to follow-ups where the
treatment of these patients is discussed, for example when a physician is ensuring the patient
how important it is to finish their course of antibiotics. However, these follow-ups can be
detrimental to both the patient and the hospital facility if they are functioning as continued
investigations in leu of tick-panel results. Supplemental testing being ordered and performed
during these visits means there are more charges being added to the patient’s bill and more
resources being used on this patient by the facility. If there was a quicker methodology in
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detecting these kinds of diseases, the savings on behalf of all parties involved would be
significant.

Conclusions and Future Directions
The predominating conclusion of this study is that investigation of tick-acquired disease
is burdensome to the patient and the hospital facility, and studying this process to better adapt
to this challenge will be imperative in the future of health care. This is evidenced by data
surrounding supplemental testing, time to diagnosis, and follow-up visits. Thirty-nine percent of
the studied patient population had supplemental testing in addition to an Accutix blood analysis
panel. Thirty-three percent of patients waited four days to receive the results of their panel,
which is likely the same days they underwent additional testing. Finally, 42% of patients required
a follow-up visit in the investigation of their tick-borne illness. Between supplemental testing and
follow-up visits taking place in the hospital, there is a significant burden placed on the facility as
these patients await their Accutix results. The days in which patients and physicians are waiting
for definite diagnosis are often the same days in which further investigation is taking place.
Ultimately, the financial obligations of the patient and testing facility are maximized in our
current process. During the peak tick seasons in New England, it would be beneficial for more
hospital facilities to study the flow of diagnoses in patients presenting with symptomology
suggesting tick-borne disease. There is abundant room for improvement in this process that
would protect the resources of both the patient and the hospital.
Another noteworthy trend that became apparent during this study was the immense
challenge of navigating the clinical presentations of tick-borne diseases. The hallmark symptoms
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in this category of infections are erythema migrans or bull’s eye rashes, fever, fatigue and
malaise. The bull’s eye rash associated with Lyme disease is an observation that is rarely actually
observed in clinical practice, and other “hallmark” symptoms like fatigue are so general to the
scope of medical practice that they are virtually useless in a differential diagnosis. This study
found that the most common reported symptom from patients who received positive test results
for tick-borne infection was myalgia. This begs the question as to whether the medical
community needs to re-visit its definition of the most common clinical presentations in tick-borne
infections. More research to determine which symptoms are most closely related to positive test
results is needed to best service clinicians and patients during peak tick season.
Despite the important implications of this study, the many limitations within it must be
acknowledged in its consideration. The patient pool size of 100 is sufficient for a small-scale
analysis, but future studies would be most effective with larger population sizes of thousands of
patients. The geographic limitations of this study are also of note. Seeing as data in these analyses
came from one single hospital and its affiliating locations, it is imperative that a larger range of
facilities be studied across the Northeast and in other areas where tick-borne illnesses are
endemic. Continuations of studies such as this should include investigation on alternative
methods of diagnosis and their effectiveness as viable alternatives to the current process. For
example, new companies such as Tick Report.com are surfacing which offer mail-in tick testing
services. The idea behind this concept is based on testing the tick directly for pathogens before
lengthy testing is done on the patient in a hospital setting. Patients who discover a tick can elect
to mail it to company headquarters and receive an electronic report within 72 hours with a
complete profile on their tick.22 The information on the tick profile might indicate the presence
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of a pathogen, at which point the patient can decide to seek further testing and possible
treatment. Concepts such as this do have their own list of limitations, the most noteworthy being
the small chance that a patient is able to recover a tick from the site of possible infection.
However, the great opportunity for a more robust set of epidemiological data on the tick
population in the Northeast is a valuable potential outcome for services such as these. Another
option to decrease the turnaround time for tick-borne infection testing could be the
development of adapted molecular assays. Many platforms already exist for the rapid detection
of bacteria and viruses via polymerase chain reaction (PCR) amplification of nucleic acids. The
GeneXpert system by Cepheid is an increasingly prevalent part of many hospital laboratories and
features assays for Influenza, C. diff, Gonorrhea and Chlamydia, and others with turnaround
times within a few hours23. With more molecular testing being made available at hospital level
to eliminate the need for send-out tests, it may be worthwhile to explore adapting these methods
for tick-borne pathogens. The ultimate goal is reducing the time to diagnosis in these patients
and avoid over-testing, over-prescribing, and consequently over-paying for both the patient and
the health care facility. Further investigation of our current methods and possible future
adaptations to them are critical if we are to conquer the diverse array of challenges presented
by tick-borne diseases.

31

References
1. Paddock CD, Lane RS, Staples JE, Labruna MB. CHANGING PARADIGMS FOR TICK-BORNE
DISEASES IN THE AMERICAS. National Academies Press (US); 2016.
https://www.ncbi.nlm.nih.gov/books/NBK390439/. Accessed November 26, 2019.
2. Wikel SK. Ticks and Tick-Borne Infections: Complex Ecology, Agents, and Host Interactions.
Vet Sci. 2018;5(2). doi:10.3390/vetsci5020060
3. Butler AD, Sedghi T, Petrini JR, Ahmadi R. Tick-borne disease preventive practices and
perceptions in an endemic area. Ticks Tick-Borne Dis. 2016;7(2):331-337.
doi:10.1016/j.ttbdis.2015.12.003
4. First multiplex test for tick-borne diseases: Promising to revolutionize diagnosis, a single
blood test can now accurately detect if someone is infected with Lyme and/or one of seven
other tick-borne diseases. ScienceDaily.
https://www.sciencedaily.com/releases/2018/02/180216110532.htm. Accessed December
3, 2019.
5. TickborneDiseases-P.pdf. https://www.cdc.gov/ticks/tickbornediseases/TickborneDiseasesP.pdf. Accessed November 21, 2019.
6. Home. Imugen. http://www.imugen.com/. Accessed December 2, 2019.
7. Prevention C-C for DC and. CDC - Babesiosis - Biology.
https://www.cdc.gov/parasites/babesiosis/biology.html. Published April 11, 2019. Accessed
December 5, 2019.
8. Babesiosis. Lyme Disease. https://www.columbia-lyme.org/babesiosis. Published April 11,
2018. Accessed November 23, 2019.
9. Guzman N, Beidas SO. Anaplasma Phagocytophilum (Anaplasmosis). In: StatPearls. Treasure
Island (FL): StatPearls Publishing; 2019. http://www.ncbi.nlm.nih.gov/books/NBK513341/.
Accessed November 23, 2019.
10. 175s.pdf. https://www.aabb.org/tm/eid/Documents/175s.pdf. Accessed November 25,
2019.
11. Tilly K, Rosa PA, Stewart PE. Biology of Infection with Borrelia burgdorferi. Infect Dis Clin
North Am. 2008;22(2):217-234. doi:10.1016/j.idc.2007.12.013
12. Kuleš J, Potocnakova L, Bhide K, et al. The Challenges and Advances in Diagnosis of VectorBorne Diseases: Where Do We Stand? Vector-Borne Zoonotic Dis. 2017;17(5):285-296.
doi:10.1089/vbz.2016.2074

32

13. Rights (OCR) O for C. Methods for De-identification of PHI. HHS.gov.
https://www.hhs.gov/hipaa/for-professionals/privacy/special-topics/deidentification/index.html. Published September 7, 2012. Accessed December 3, 2019.
14. Causes, consequences, and reversal of immune system aging.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582124/. Accessed December 16, 2019.
15. Urgent Care Center vs. Emergency Room | Solv. https://www.solvhealth.com/faq/urgentcare-center-vs-emergency-room. Accessed December 16, 2019.
16. Lyme Disease | Lyme Disease | CDC. https://www.cdc.gov/lyme/index.html. Accessed
December 16, 2019.
17. Are serological tests of any value in the diagnosis of Lyme disease ? | ALDF.
https://www.aldf.com/are-serological-tests-of-any-value-in-the-diagnosis-of-lyme-disease2/. Accessed December 16, 2019.
18. B Lymphocytes and Humoral Immunity | Microbiology.
https://courses.lumenlearning.com/microbiology/chapter/b-lymphocytes-and-humoralimmunity/. Accessed December 9, 2019.
19. Treatment of tick-borne diseases. - PubMed - NCBI.
https://www.ncbi.nlm.nih.gov/pubmed/12243610. Accessed December 16, 2019.
20. Tick Bite Prophylaxis | Tick-borne Diseases | Ticks | CDC.
https://www.cdc.gov/ticks/tickbornediseases/tick-bite-prophylaxis.html. Accessed
December 16, 2019.
21. Be Antibiotics Aware: Smart Use, Best Care | Features | CDC.
https://www.cdc.gov/features/antibioticuse/index.html. Accessed December 16, 2019.
22. TickReport. https://www.tickreport.com/. Accessed December 16, 2019.
23. Cepheid | GeneXpert Xpress. https://www.cepheid.com/en_US/systems/GeneXpertFamily-of-Systems/GeneXpert-Xpress. Accessed March 2, 2020.

33

